PDCD1 and cancer: To date, immune checkpoint inhibitors (ICI) have been designed to be able to act against CTLA-4/B7 and PD-1/PD-L1pathways, and the efficacy of combined immunotherapy with MoAb in cancer treatment has recently been applied, showing higher clinical efficacy compared to either agent individually [97].